This clinical trial for patients with ALK+ lung cancer seeks to understand and innovate future treatments.
The SPACEWALK trial (Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance) studies how ALK-positive lung cancer changes, starts growing again, and/or comes back after treatment with an ALK targeted therapy. The trial is led by Dr. Mark Award of Dana Farber Cancer Institute. It was originally launched by Dr. Geoffrey Oxnard of DFCI, a prior chair of GO2 for Lung Cancer’s Scientific Leadership Board.
Patients whose cancer is growing after ALK targeted therapy [Alecensa (alectinib), Alunbrig (brigatinib), Zykadia (ceritinib), or Lorbrena (lorlatinib)] have their blood drawn and sent for analysis of biomarker changes. The results are used to understand ALK biology and are also sent to the oncologist and patient to help inform treatment decisions. The trial is still open and recruiting but some early scientific results have already been published: https://doi.org/10.1016/j.jtocrr.2021.100151
Patients in any location in the United States, seeing any oncologist, can participate in the study.
For more information or to learn how to participate in the study, visit:
https://alcmi.net/research/spacewalk-study/
or call 844-44-SPACE (844-447-7223).